Literature DB >> 25200945

Macrophage activation syndrome in Kawasaki disease: more common than we thought?

Wei Wang1, Fangqi Gong2, Weihua Zhu1, Songling Fu1, Qing Zhang1.   

Abstract

OBJECTIVES: To analyze the clinical characteristics, treatment, and outcomes of Kawasaki Disease (KD) patients associated with macrophage activation syndrome (MAS) and to compare two diagnostic standards (the HLH 2009 and Ravelli׳s criteria).
METHODS: All of the studied patients with Kawasaki Disease (KD) were treated at The Children׳s Hospital, Zhejiang University School of Medicine, during 2007-2010. Clinical and laboratory findings were analyzed.
RESULTS: In 719 KD patients, eight patients (1.11%, 81.3 ± 49.4 months, all male) were diagnosed by Ravelli׳s criteria, but only three (0.42%) patients were diagnosed by the HLH 2009 criteria. Aspartate aminotransferase increased significantly in all cases. Alanine aminotransferase, lactate dehydrogenase, and serum ferritin increased significantly in seven cases. Cytopenia and hypertriglyceridemia (>1.5mmol/L) were found in six and five cases, respectively. Hypofibrinogenemia (<1.5g/L) was found in two cases. Three cases showed evidence of hemophagocytosis, but only one case met the HLH 2009 criteria. Ectasia of the coronary arteries occurred in two cases. Seven patients were non-responsive to IVIG. One case died after the combined application of DXM, VP16, and CSA.
CONCLUSIONS: MAS may be a frequently under-recognized complication of KD, because the understanding of complications and diagnostic criteria are still in progress. The HLH 2009 criteria have low sensitivity and specificity for the diagnosis of MAS complicating KD. When hepatosplenomegaly is present in KD patients with abnormal laboratory findings, such as cytopenia, liver dysfunction, hyperferritinemia, elevated serum LDH, hypofibrinogenemia, and hypertriglyceridemia, the presence of MAS should be considered.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kawasaki Disease; Macrophage activation syndrome

Mesh:

Substances:

Year:  2014        PMID: 25200945     DOI: 10.1016/j.semarthrit.2014.07.007

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  30 in total

1.  Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.

Authors:  Li-Xia Zou; Yun Zhu; Li Sun; Hui-Hui Ma; Si-Rui Yang; Hua-Song Zeng; Ji-Hong Xiao; Hai-Guo Yu; Li Guo; Yi-Ping Xu; Mei-Ping Lu
Journal:  World J Pediatr       Date:  2019-10-14       Impact factor: 2.764

Review 2.  Macrophage activation syndrome in juvenile dermatomyositis: a systematic review.

Authors:  Dimitri Poddighe; Kaisar Dauyey
Journal:  Rheumatol Int       Date:  2019-09-16       Impact factor: 2.631

Review 3.  Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management.

Authors:  Lauren A Henderson; Randy Q Cron
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

Review 4.  MIS-C related to SARS-CoV-2 infection: a narrative review of presentation, differential diagnosis, and management.

Authors:  Salika Gadiwala; Ayushi Mistry; Sejal Patel; Avanthika Chaithanya; Stuti Pathak; Travis Satnarine; Daria Bekina-Sreenivasan; Abdul Akim Bakarr; Bibhuti Bhusan Das; Raja Chandra Chakinala; Saurabhkumar Patel; Sathya Areti
Journal:  Infez Med       Date:  2022-09-01

5.  Evaluation of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis: single center experience over a one-year period.

Authors:  Kenan Barut; Gözde Yücel; Ada Bulut Sinoplu; Sezgin Şahin; Amra Adroviç; Özgür Kasapçopur
Journal:  Turk Pediatri Ars       Date:  2015-12-01

6.  High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.

Authors:  Marie Lind-Holst; Ulla Birgitte Hartling; Anne Estmann Christensen
Journal:  BMJ Case Rep       Date:  2019-08-04

Review 7.  IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.

Authors:  Perrine Dusser; Isabelle Koné-Paut
Journal:  Front Pharmacol       Date:  2017-03-28       Impact factor: 5.810

8.  Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.

Authors:  Leora R Feldstein; Erica B Rose; Steven M Horwitz; Jennifer P Collins; Margaret M Newhams; Mary Beth F Son; Jane W Newburger; Lawrence C Kleinman; Sabrina M Heidemann; Amarilis A Martin; Aalok R Singh; Simon Li; Keiko M Tarquinio; Preeti Jaggi; Matthew E Oster; Sheemon P Zackai; Jennifer Gillen; Adam J Ratner; Rowan F Walsh; Julie C Fitzgerald; Michael A Keenaghan; Hussam Alharash; Sule Doymaz; Katharine N Clouser; John S Giuliano; Anjali Gupta; Robert M Parker; Aline B Maddux; Vinod Havalad; Stacy Ramsingh; Hulya Bukulmez; Tamara T Bradford; Lincoln S Smith; Mark W Tenforde; Christopher L Carroll; Becky J Riggs; Shira J Gertz; Ariel Daube; Amanda Lansell; Alvaro Coronado Munoz; Charlotte V Hobbs; Kimberly L Marohn; Natasha B Halasa; Manish M Patel; Adrienne G Randolph
Journal:  N Engl J Med       Date:  2020-06-29       Impact factor: 91.245

9.  Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin.

Authors:  Alessia Alunno; Francesco Carubbi; Javier Rodríguez-Carrio
Journal:  RMD Open       Date:  2020-05

Review 10.  The "Three Italy" of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia.

Authors:  Carla Prezioso; Maria Elena Marcocci; Anna Teresa Palamara; Giovanna De Chiara; Valeria Pietropaolo
Journal:  J Neurovirol       Date:  2020-06-16       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.